Onset of activity of fluralaner (BRAVECTO¿) against Ctenocephalides felis on dogs

Taenzler, Janina; Wengenmayer, Christina; Williams, Heike; Fourie, Josephus J.; Zschiesche, Eva; Roepke, Rainer K. A.; Heckeroth, Anja R.

doi:10.1186/preaccept-1563099569137345

Cited by 21 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluralaner (Bravecto®; Merck Animal Health) is the only isoxazoline that provides 12 weeks of immediate and persistent flea and tick efficacy for dogs [6–9]. Field studies in the USA, Europe and Australia demonstrated the safety and efficacy of orally administered fluralaner for reducing flea and tick infestations on dogs [10–12].…”

Section: Introductionmentioning

confidence: 99%

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations

Meadows¹,

Guerino²,

Sun³

2017

Parasites Vectors

View full text Add to dashboard Cite

BackgroundFleas are a common ectoparasite of domestic cats and there is a need for novel treatments that improve feline flea control.MethodsThis investigator-blinded, multi-center randomized, positive-controlled study evaluated the flea control in cats provided by a single owner-applied treatment with a fluralaner topical formulation compared with a positive control. Households with up to five healthy cats, all at least 12 weeks of age and weighing at least 1.2 kg (2.6 lb), were randomized in an approximate 3:1 ratio of fluralaner to positive control. All cats in households randomized to the positive control group were dispensed three treatments, at 4-week intervals, of a commercial formulation of fipronil/(S)-methoprene. All cats in households randomized to the fluralaner group were dispensed an initial treatment at enrollment and a second treatment at week 12 for an additional 3-week observation of treatment safety. One primary cat with at least five live fleas at enrollment was randomly selected within each household. Flea counts were performed on all primary cats at 4-week intervals through week 12. Efficacy measurement was based on reduction in flea counts from baseline. Treatment was considered effective at weeks 4, 8 and 12 if mean live flea count reductions were 90% or greater and statistically significantly different (P ≤ 0.05) from counts at enrollment.ResultsIn 18 investigational veterinary clinics across 11 USA states, 116 households (224 cats) were randomized to receive topical fluralaner and 45 households (87 cats) were randomized to the fipronil-methoprene combination. Fluralaner was demonstrated to be effective at 4 weeks (99.1% flea count reduction), 8 weeks (99.5%), and 12 weeks (99.0%), and all reductions were significantly different from the enrollment count (all P < 0.0001). The fipronil-methoprene combination was < 90% effective at each post-treatment assessment, with peak efficacy of 75.4% at 12 weeks (all P < 0.0001). No treatment-related serious adverse events were reported in either group.ConclusionsOwner-applied fluralaner topical treatment was safe in cats and was highly effective in killing fleas over the subsequent 12 weeks.

show abstract

Section: Introductionmentioning

confidence: 99%

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations

Meadows¹,

Guerino²,

Sun³

2017

Parasites Vectors

View full text Add to dashboard Cite

show abstract

“…In dogs experimentally infested with fleas, the fluralaner chewable tablet showed early onset of flea killing at 2 h and 100% flea killing at 12 h post-administration [1]. This high level of efficacy was sustained for 12 weeks, with 98.0% to 100% reductions in mean live flea counts at 8, 12, and 24 h after experimental reinfestations.…”

Section: Introductionmentioning

confidence: 99%

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations

Meadows¹,

Guerino²,

Sun³

2017

Parasites Vectors

View full text Add to dashboard Cite

BackgroundOrally administered fluralaner effectively controls fleas and ticks on dogs for 12 weeks. This study evaluates the flea control efficacy achieved with topically applied fluralaner in dogs.MethodsThis investigator-blinded, multi-center randomized, positive controlled study evaluated flea control efficacy in dogs following a single owner-applied treatment of topical fluralaner. A positive control group received three treatments, at 4-week intervals, of a commercial formulation of fipronil/(S)-methoprene. All dogs in households randomized to the fluralaner group were dispensed an initial treatment at enrollment and a second treatment at week 12 for an additional 3-week observation of treatment safety. Households with up to five healthy dogs, all at least 12 weeks of age and weighing at least 2 kg (4.4 lb), were randomized in a ratio of 3:1 of fluralaner to positive control. Within households, one primary dog with at least 10 live fleas at enrollment was randomly selected. Flea counts were performed on all primary dogs every 4 weeks through week 12. Efficacy measurement was based on reduction from baseline flea counts. Treatment was considered effective if geometric mean live flea count reductions at weeks 4, 8, and 12 were 90% or greater and significantly different from counts at enrollment. In addition, for each time point the arithmetic mean live flea counts, the efficacy based on arithmetic means, the number and percentage of dogs with at least a 90% reduction in flea count, and the number and percentage of flea free dogs were calculated. Statistical comparisons were also made between treatment groups.ResultsAt 12 sites, across 10 states, 121 households (221 dogs) were randomized to receive fluralaner and 44 households (100 dogs) were randomized to receive the positive control. Fluralaner was demonstrated to be significantly effective (all P ≤ 0.0001) at 4 weeks (99.8% reduction), 8 weeks (99.9%), and 12 weeks (99.9%). The positive control was significantly different from baseline (all P ≤ 0.0001) and showed a reduction of 81.2% at 4 weeks and was effective at 8 weeks (90.3%) and 12 weeks (93.0%). Arithmetic mean flea count reductions for the fluralaner group at 4, 8, and 12 weeks were 99.8, 99.9, and 99.9%, respectively. For the positive control, arithmetic mean flea count reductions were 58.8, 75.3, and 80.8% at 4, 8, and 12 weeks, respectively. No treatment-related serious adverse events were reported in either group.ConclusionsOwner-applied topical fluralaner treatment was safe in dogs and provided ≥ 99.8% flea control efficacy for 12 weeks.

show abstract

“…Fluralaner belongs to this new class and has prolonged activity against fleas and ticks after a single oral dose (Kilp et al, 2014) of 25 mg/kg, with no adverse effects observed during a safety trial, even at higher doses (Walther et al, 2014). No side effects were observed by the authors of previous studies either (Taenzler et al, 2014;Wengenmayer et al, 2014;Fourie et al, 2015). However, one study reported inappetence, vomiting, and diarrhea (Rohdich et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of fluralaner against canine generalized demodicosis

et al. 2019

View full text Add to dashboard Cite

show abstract

Onset of activity of fluralaner (BRAVECTO¿) against Ctenocephalides felis on dogs

Abstract: Single oral fluralaner administration rapidly eliminates existing flea infestations and provides excellent protection against fleas over 12 weeks following treatment.

Cited by 21 publications

References 8 publications

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations

Efficacy of fluralaner against canine generalized demodicosis

Contact Info

Product

Resources

About